The burgeoning field of obesity management has witnessed remarkable advancements with the emergence of dual GLP-3 receptor agonists, notably Retatrutide and Trizepatide. These novel therapies represent a significant departure from traditional GLP-3 receptor agonists, exhibiting superior efficacy in promoting significant weight reduction and improvi

Retatrutide and trizepatide are a novel class of medications that bind to both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These combined receptor agonists exhibit exceptional therapeutic efficacy in the treatment of type 2 diabetes. Retatrutide, a once-weekly subcutaneous injection, engages